© 2021 MJH Life Sciences and HCPLive - Clinical news for connected physicians. All rights reserved.
© 2021 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
January 19, 2021
Dr. Matthew Brams presented new data showing the efficacy of CTx-1301 for ADHD.
January 18, 2021
CTx-1301's formulation enables 3 different doses within 1 pill for ADHD.
Researchers are prepared a phase 3 trial testing the treatment in adults with ADHD.
The role of many in psychiatry has changed during the COVID-19 pandemic.
Such scores could provide insight into the significant comorbidity rate of ADHD and other youth mood and emotional dysregulation issues.
January 17, 2021
Personalized, daily self-reporting for patients could influence future therapeutic strategies.
Randomized controlled trials are needed to evaluate their efficacy in comparison with in-person group meetings.
A pair of researchers present plans to improve collaboration with other professionals in ADHD.
The likelihood of smoking addiction is associated with traits also closely associated with worsened ADHD.
An ADHD coach can work on more goal-based plans for individuals with ADHD.